on Theranexus (EPA:ALTHX)
Theranexus Publishes its Letter to Shareholders
The biopharmaceutical company Theranexus, which specializes in the treatment of rare neurological diseases, announced the publication of its letter to shareholders on January 9, 2025. This document is available on the company's website in the Shareholders section.
Theranexus encourages its shareholders to subscribe to receive its communications. The company, which emerged from the CEA, stands out with an innovative platform dedicated to drug candidates for rare neurological disorders. Its first clinical project concerns Batten disease.
However, Theranexus highlights limited financial outlook through the first quarter of 2026, which could result in significant dilution for its shareholders. Economic and market fluctuations add to current uncertainties.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news